Dana Alexander brings more than 20 years of experience in biopharmaceutical operations. Mr. Alexander was most recently Head of Viral Vector Business Operations and Site General Manager at Brammer Bio, now part of Thermo Fisher Scientific. While at Brammer Bio, he led the start-up of late stage and commercial viral vector operations at their Cambridge, MA site, including production of AAV, lentiviral, adenoviral, herpesviral, and retroviral vectors with adherent and suspension platforms.

Prior to Brammer, Mr. Alexander held senior operational and manufacturing leadership positions at Anika Therapeutics and Genzyme, a Sanofi Company. During his 14-year tenure at Genzyme, Mr. Alexander led manufacturing at their flagship commercial biologics plant including overseeing production planning and execution, bringing new manufacturing capacity on-line, and implementing new production and quality management systems. He also had led the construction, start-up, and global licensure of a new commercial cGMP cell culture facility, managed Chemistry, Manufacturing and Control (CMC) activities for a variety of late-stage and commercial biologic products, and led operational product teams across complex global supply networks.

Mr. Alexander holds a MBA from Boston University, and a BS in Chemical Engineering from Northeastern University.